## Pascal Bonaventure

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8603862/publications.pdf Version: 2024-02-01

		71102	98798
108	5,041	41	67
papers	citations	h-index	g-index
111 all docs	111 docs citations	111 times ranked	4339 citing authors

#	Article	IF	CITATIONS
1	Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 142-151.	2.5	210
2	Relaxin-3 in GABA projection neurons of nucleus incertus suggests widespread influence on forebrain circuits via G-protein-coupled receptor-135 in the rat. Neuroscience, 2007, 144, 165-190.	2.3	183
3	8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. European Journal of Pharmacology, 2004, 487, 125-132.	3.5	169
4	INSL5 Is a High Affinity Specific Agonist for GPCR142 (GPR100). Journal of Biological Chemistry, 2005, 280, 292-300.	3.4	167
5	Nuclei and subnuclei gene expression profiling in mammalian brain. Brain Research, 2002, 943, 38-47.	2.2	151
6	Selective Blockade of 5-Hydroxytryptamine (5-HT)7 Receptors Enhances 5-HT Transmission, Antidepressant-Like Behavior, and Rapid Eye Movement Sleep Suppression Induced by Citalopram in Rodents. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 690-698.	2.5	149
7	Pharmacological characterization of a novel centrally permeable <scp>P2X7</scp> receptor antagonist: <scp>JNJ</scp> â€47965567. British Journal of Pharmacology, 2013, 170, 624-640.	5.4	148
8	Relaxin-3/Insulin-Like Peptide 5 Chimeric Peptide, a Selective Ligand for G Protein-Coupled Receptor (GPCR)135 and GPCR142 over Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 7. Molecular Pharmacology, 2005, 67, 231-240.	2.3	145
9	Histamine H3 receptor antagonists: From target identification to drug leads. Biochemical Pharmacology, 2007, 73, 1084-1096.	4.4	140
10	R3(BΔ23–27)R/I5 Chimeric Peptide, a Selective Antagonist for GPCR135 and GPCR142 over Relaxin Receptor LGR7. Journal of Biological Chemistry, 2007, 282, 25425-25435.	3.4	131
11	Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology, 2011, 215, 191-203.	3.1	130
12	Distribution of relaxinâ€3 and RXFP3 within arousal, stress, affective, and cognitive circuits of mouse brain. Journal of Comparative Neurology, 2010, 518, 4016-4045.	1.6	123
13	Distribution of G-Protein-Coupled Receptor (GPCR)135 Binding Sites and Receptor mRNA in the Rat Brain Suggests a Role for Relaxin-3 in Neuroendocrine and Sensory Processing. Neuroendocrinology, 2004, 80, 298-307.	2.5	121
14	Genomic and functional conservation of sedative-hypnotic targets in the zebrafish. Pharmacogenetics and Genomics, 2007, 17, 237-253.	1.5	114
15	Detailed mapping of serotonin 5-HT1B and 5-HT1D receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function. Neuroscience, 1997, 82, 469-484.	2.3	102
16	Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human brain using [3H]GR 125743. Brain Research, 2001, 915, 47-57.	2.2	99
17	Pharmacological Characterization of Relaxin-3/INSL7 Receptors GPCR135 and GPCR142 from Different Mammalian Species. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 83-95.	2.5	88
18	Mapping of serotonin 5-HT4 receptor mRNA and ligand binding sites in the post-mortem human brain. , 2000, 36, 35-46.		86

#	Article	IF	CITATIONS
19	Reconsideration of 5-Hydroxytryptamine (5-HT)7Receptor Distribution Using [3H]5-Carboxamidotryptamine and [3H]8-Hydroxy-2-(di-n-propylamino)tetraline: Analysis in Brain of 5-HT1AKnockout and 5-HT1A/1BDouble-Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 240-248.	2.5	79
20	A Selective Orexin-1 Receptor Antagonist Attenuates Stress-Induced Hyperarousal without Hypnotic Effects. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 590-601.	2.5	78
21	In Vitro Receptor Binding and In Vivo Receptor Occupancy in Rat and Guinea Pig Brain: Risperidone Compared with Antipsychotics Hitherto Used. The Japanese Journal of Pharmacology, 1995, 69, 399-412.	1.2	76
22	Translational Evaluation of JNJ-18038683, a 5-Hydroxytryptamine Type 7 Receptor Antagonist, on Rapid Eye Movement Sleep and in Major Depressive Disorder. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 429-440.	2.5	74
23	Selective orexin receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4761-4769.	2.2	69
24	Pharmacology of a Novel Central Nervous System–Penetrant P2X7 Antagonist JNJ-42253432. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 628-641.	2.5	67
25	Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine7 receptor distribution and uncovers 8-hydroxy-2-(di-n-propylamino)tetralin interaction with α2 adrenergic receptors. Neuroscience, 2004, 124, 901-911.	2.3	63
26	Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 471-482.	2.5	62
27	Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Frontiers in Neuroscience, 2014, 8, 28.	2.8	61
28	Molecular cloning, expression and tissue distribution of glial-cell-line-derived neurotrophic factor family receptor alpha-3 (GFRalpha-3). FEBS Journal, 1998, 251, 622-630.	0.2	58
29	OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO <sub>2</sub> -INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES. Depression and Anxiety, 2015, 32, 671-683.	4.1	57
30	Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behavioural Pharmacology, 2008, 19, 153-159.	1.7	55
31	GPR139, an Orphan Receptor Highly Enriched in the Habenula and Septum, Is Activated by the Essential Amino Acids I-Tryptophan and I-Phenylalanine. Molecular Pharmacology, 2015, 88, 911-925.	2.3	55
32	JNJ-10181457, a selective non-imidazole histamine H3 receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology, 2009, 56, 1131-1137.	4.1	52
33	Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex. Journal of Neurochemistry, 2010, 115, 475-482.	3.9	51
34	4-Methyl-6,7-dihydro-4 <i>H</i> -triazolo[4,5- <i>c</i> ]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate. Journal of Medicinal Chemistry, 2017, 60, 4559-4572.	6.4	51
35	Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor. Journal of Pharmacology and Experimental Therapeutics. 2004. 308. 1130-1137.	2.5	49
36	Metabolic and Neuroendocrine Responses to RXFP3 Modulation in the Central Nervous System. Annals of the New York Academy of Sciences, 2009, 1160, 242-249.	3.8	47

#	Article	IF	CITATIONS
37	Structure and function of the amygdaloid NPY system: NPY Y2 receptors regulate excitatory and inhibitory synaptic transmission in the centromedial amygdala. Brain Structure and Function, 2016, 221, 3373-3391.	2.3	47
38	G-Protein-Coupled Receptor (GPCR)-142 Does Not Contribute to Relaxin-3 Binding in the Mouse Brain: Further Support that Relaxin-3 Is the Physiological Ligand for GPCR135. Neuroendocrinology, 2005, 82, 139-150.	2.5	45
39	In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor. Psychopharmacology, 2010, 208, 265-277.	3.1	45
40	Pharmacological Blockade of Serotonin 5-HT7 Receptor Reverses Working Memory Deficits in Rats by Normalizing Cortical Glutamate Neurotransmission. PLoS ONE, 2011, 6, e20210.	2.5	44
41	JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology, 2011, 214, 829-841.	3.1	43
42	Pharmacological characterization of JNJ-28583867, a histamine H3 receptor antagonist and serotonin reuptake inhibitor. European Journal of Pharmacology, 2007, 576, 43-54.	3.5	42
43	The novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist, JNJ-31020028, tested in animal models of alcohol consumption, relapse, and anxiety. Alcohol, 2011, 45, 567-576.	1.7	42
44	Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. The Histochemical Journal, 1996, 28, 791-799.	0.6	40
45	5HT1B and 5HT1D receptor mRNA differential co-localization with peptide mRNA in the guinea pig trigeminal ganglion. NeuroReport, 1998, 9, 641-645.	1.2	40
46	Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X <sub>7</sub> Antagonists. ACS Medicinal Chemistry Letters, 2013, 4, 419-422.	2.8	40
47	A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334. European Journal of Pharmacology, 2015, 765, 551-559.	3.5	40
48	Novel Octahydropyrrolo[3,4- <i>c</i> ]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate. Journal of Medicinal Chemistry, 2015, 58, 5620-5636.	6.4	39
49	Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation. Frontiers in Pharmacology, 2017, 8, 357.	3.5	39
50	Co-localization of 5-HT1B- and 5-HT1D receptor mRNA in serotonergic cell bodies in guinea pig dorsal raphé nucleus: a double labeling in situ hybridization histochemistry study. Neuroscience Letters, 1998, 254, 113-116.	2.1	38
51	Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1047-1051.	2.2	35
52	Orexin Depolarizes Central Amygdala Neurons via Orexin Receptor 1, Phospholipase C and Sodium-Calcium Exchanger and Modulates Conditioned Fear. Frontiers in Neuroscience, 2018, 12, 934.	2.8	34
53	In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. European Journal of Pharmacology, 2008, 587, 141-146.	3.5	32
54	Relaxin Family Peptides and Receptors in Mammalian Brain. Annals of the New York Academy of Sciences, 2009, 1160, 226-235.	3.8	31

PASCAL BONAVENTURE

#	Article	IF	CITATIONS
55	Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3157-3163.	2.2	30
56	Zolpidem Reduces Hippocampal Neuronal Activity in Freely Behaving Mice: A Large Scale Calcium Imaging Study with Miniaturized Fluorescence Microscope. PLoS ONE, 2014, 9, e112068.	2.5	29
57	Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Translational Psychiatry, 2020, 10, 308.	4.8	29
58	5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor. Neuropharmacology, 2009, 56, 448-454.	4.1	28
59	Identification and SAR of Glycine Benzamides as Potent Agonists for the GPR139 Receptor. ACS Medicinal Chemistry Letters, 2015, 6, 1015-1018.	2.8	28
60	Chronic administration of the Y2 receptor antagonist, JNJ-31020028, induced anti-depressant like-behaviors in olfactory bulbectomized rat. Neuropeptides, 2012, 46, 329-334.	2.2	27
61	The Zinc Transporter SLC39A7 (ZIP7) Is Essential for Regulation of Cytosolic Zinc Levels. Molecular Pharmacology, 2018, 94, 1092-1100.	2.3	27
62	Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus. European Journal of Pharmacology, 2013, 715, 21-25.	3.5	26
63	Molecular and pharmacological characterization of serotonin 5-HT2A and 5-HT2B receptor subtypes in dog. European Journal of Pharmacology, 2005, 513, 181-192.	3.5	24
64	Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 39-43.	2.2	24
65	Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: Identification of candidates for clinical development. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4210-4214.	2.2	24
66	Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. European Journal of Pharmacology, 2011, 667, 120-128.	3.5	24
67	NPY Y2 receptors in the central amygdala reduce cued but not contextual fear. Neuropharmacology, 2015, 99, 665-674.	4.1	24
68	Direct Imaging of Hippocampal Epileptiform Calcium Motifs Following Kainic Acid Administration in Freely Behaving Mice. Frontiers in Neuroscience, 2016, 10, 53.	2.8	22
69	Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists. European Journal of Medicinal Chemistry, 2009, 44, 4413-4425.	5.5	21
70	Selective Inhibition of Orexin-2 Receptors Prevents Stress-Induced ACTH Release in Mice. Frontiers in Behavioral Neuroscience, 2017, 11, 83.	2.0	20
71	GPR139 and Dopamine D2 Receptor Co-express in the Same Cells of the Brain and May Functionally Interact. Frontiers in Neuroscience, 2019, 13, 281.	2.8	20
72	In Vitro Pharmacological Characterization of RXFP3 Allosterism: An Example of Probe Dependency. PLoS ONE, 2012, 7, e30792.	2.5	19

#	Article	IF	CITATIONS
73	Identification of the domains in RXFP4 (GPCR142) responsible for the high affinity binding and agonistic activity of INSL5 at RXFP4 compared to RXFP3 (GPCR135). European Journal of Pharmacology, 2008, 590, 43-52.	3.5	18
74	The Future Antihistamines: Histamine H3 and H4 Receptor Ligands. Advances in Experimental Medicine and Biology, 2010, 709, 125-140.	1.6	18
75	Screening for modulators of neural network activity in 3D human iPSC-derived cortical spheroids. PLoS ONE, 2020, 15, e0240991.	2.5	18
76	Novel non-peptidic neuropeptide Y Y 2 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1239-1242.	2.2	17
77	Substituted 5,6-(Dihydropyrido[3,4- <i>d</i> ]pyrimidin-7(8 <i>H</i> )-yl)-methanones as P2X7 Antagonists. ACS Chemical Neuroscience, 2016, 7, 498-504.	3.5	17
78	2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2103-2108.	2.2	15
79	Novel Benzamide-Based Histamine H3 Receptor Antagonists: The Identification of Two Candidates for Clinical Development. ACS Medicinal Chemistry Letters, 2015, 6, 450-454.	2.8	15
80	Re-evaluation of Adrenocorticotropic Hormone and Melanocyte Stimulating Hormone Activation of GPR139 in Vitro. Frontiers in Pharmacology, 2018, 9, 157.	3.5	14
81	The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y2 receptor. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5552-5556.	2.2	13
82	Diamine-based human histamine H3 receptor antagonists: (4-Aminobutyn-1-yl)benzylamines. European Journal of Medicinal Chemistry, 2009, 44, 4098-4106.	5.5	12
83	PET Brain Imaging of Neuropeptide Y2 Receptors Using <i>N</i> - <sup>11</sup> C-Methyl-JNJ-31020028 in Pigs. Journal of Nuclear Medicine, 2014, 55, 635-639.	5.0	12
84	Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Frontiers in Behavioral Neuroscience, 2014, 8, 453.	2.0	12
85	Hypothalamic orexin's role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model. Psychoneuroendocrinology, 2016, 65, 127-137.	2.7	12
86	Benzylamine histamine H3 antagonists and serotonin reuptake inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4799-4803.	2.2	11
87	In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist. Frontiers in Pharmacology, 2019, 10, 273.	3.5	11
88	Recent Progress in Relaxinâ€3â€Related Research. Annals of the New York Academy of Sciences, 2005, 1041, 47-60.	3.8	10
89	2-Aryloxymethylmorpholine histamine H3 antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5796-5799.	2.2	9
90	Antipsychotics and neuropeptides: The atypical profile of CI-943 and its relationship to neurotensin. Neuroscience and Biobehavioral Reviews, 1995, 19, 519-531.	6.1	8

#	Article	IF	CITATIONS
91	Recent Advances on the 5-HT5A, 5-HT6 and 5-HT7 Receptors. Annual Reports in Medicinal Chemistry, 2008, , 25-42.	0.9	8
92	Mutagenesis studies of neuropeptide S identify a suitable peptide tracer for neuropeptide S receptor binding studies and peptides selectively activating the 1107 variant of human neuropeptide S receptor. European Journal of Pharmacology, 2010, 635, 27-33.	3.5	8
93	In vivo Calcium Imaging Reveals That Cortisol Treatment Reduces the Number of Place Cells in Thy1-GCaMP6f Transgenic Mice. Frontiers in Neuroscience, 2019, 13, 176.	2.8	8
94	Probing the Functional Domains of Relaxinâ€3 and the Creation of a Selective Antagonist for RXFP3/GPCR135 over Relaxin Receptor RXFP1/LGR7. Annals of the New York Academy of Sciences, 2009, 1160, 31-37.	3.8	7
95	Novel tetrahydropyrido[3,2-c]pyrroles as 5-HT7 antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 42-44.	2.2	7
96	Pharmacological or genetic orexin1 receptor inhibition attenuates MK-801 induced glutamate release in mouse cortex. Frontiers in Neuroscience, 2014, 8, 107.	2.8	7
97	Exploration of Structure-Activity Relationships for Dual Serotonin Transporter Reuptake Inhibitors-Histamine H3 Receptor Antagonists. Current Topics in Medicinal Chemistry, 2010, 10, 596-616.	2.1	6
98	Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793. ACS Medicinal Chemistry Letters, 2020, 11, 2002-2009.	2.8	6
99	Utilizing Miniature Fluorescence Microscopy to Image Hippocampal Place Cell Ensemble Function in Thy1.GCaMP6f Transgenic Mice. Current Protocols in Pharmacology, 2018, 82, e42.	4.0	5
100	Novel substituted pyrrolidines are high affinity histamine H3 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2755-2760.	2.2	4
101	Corrigendum to "Hypothalamic orexin's role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model―[Psychoneuroendocrinology 65 (2016) 127–137]. Psychoneuroendocrinology, 2016, 73, 275.	2.7	4
102	Discovery and SAR studies of 2-alkyl-3-phenyl-2,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepines as 5-HT7/2 inhibitors leading to the identification of a clinical candidate. Bioorganic and Medicinal Chemistry Letters, 2021, 31, 127669.	2.2	3
103	The discovery of potent selective NPY Y2 antagonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4141-4144.	2.2	2
104	Mutagenesis of GPR139 reveals ways to create gain or loss of function receptors. Pharmacology Research and Perspectives, 2019, 7, e00466.	2.4	1
105	Putative role of GPR139 on sleep modulation using pharmacological and genetic rodent models. European Journal of Pharmacology, 2020, 882, 173256.	3.5	1
106	266. Use of Miniature Fluorescence Microscopes to Investigate Place Cell Ensemble Dysfunction in a Mouse Model of Chronic Stress. Biological Psychiatry, 2017, 81, S109.	1.3	0
107	161. A Pilot Screen for Neurite Growth-Promoting Compounds: A Comparison between Human iPS and Primary Rodent Neurons. Biological Psychiatry, 2017, 81, S67.	1.3	0
108	Relaxin-3 Linked to Depression: Evidence from Relaxin-3 KO Mice , 2010, , P1-202-P1-202.		0